Dermatologists Highlight Flexible Approaches for Biologics and Oral Therapies at RAD 2025
NASHVILLE, Tenn. – Emerging flexible dosing strategies for atopic dermatitis (AD) treatments could better align with patients’ fluctuating symptoms and lifestyles, according to a panel discussion at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.
Redefining Treatment Paradigms
Dr. Raj Chovatiya, clinical associate professor at Rosalind Franklin University, emphasized the growing importance of dose flexibility in AD management. “In the real world, patients want medications that fit their lives,” Chovatiya told conference attendees. “With AD’s waxing-and-waning nature, we need treatment plans that adapt to where patients are in their disease journey.”
The dermatology researcher noted that while clinical trials typically test continuous dosing, real-world evidence now supports more adaptable approaches for both biologics and oral therapies.
Identifying Candidates for Flexible Dosing
Chovatiya identified optimal candidates for adjusted regimens: “Patients achieving high levels of symptom control respond best to dose flexibility. For biologics, we can sometimes extend intervals to every 4-8 weeks for those doing well.”
He shared clinical insights on two treatment categories:
Oral Therapies
- Best for patients with seasonal flares or excellent symptom control
- May allow intermittent use during active periods
- Real-world evidence shows some patients maintain clearance with reduced frequency
Biologics
- Year-round treatment generally recommended
- Several agents (tralokinumab, lebrikizumab, nemolizumab) have label-approved extended dosing options
- Dupilumab data supports potential 4-8 week intervals for responders
Balancing Evidence with Clinical Judgment
While acknowledging limited formal studies on flexible dosing, Chovatiya emphasized: “We’re seeing this work in practice. The key is maintaining efficacy while improving quality of life – that’s where personalized medicine shines in dermatology.”
The discussion concluded with consensus on the need for more research to establish evidence-based guidelines for tailored dosing approaches in AD management.
Related Topics:
